{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:45:03Z","timestamp":1781509503380,"version":"3.54.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"publisher","award":["5790283"],"award-info":[{"award-number":["5790283"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rakel and Otto Kr. Bruun's Legacy"},{"name":"Oslo University Hospital Foundation"},{"name":"Unifor Frimed"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tumour rupture is a strong predictor of poor outcome in gastrointestinal stromal tumours (GISTs) of the stomach and small intestine. The objective was to determine whether tumour genotype was associated with risk of rupture.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Rupture was classified according to the definition proposed by the Oslo Sarcoma Group. Since January 2000, data were registered retrospectively for all patients at Oslo University Hospital undergoing surgery for localized GIST of the stomach or small intestine. Tumour genotype was analysed by Sanger sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and nine patients with mutation data available were identified. Tumour rupture occurred in 37 patients. Among the 155 patients with KIT exon 11 mutations, an increased risk of rupture was observed with a deletion or insertion\u2013deletion (25 of 86, 29 per cent) compared with substitutions (5 of 50, 10 per cent) or duplications\/insertions (2 of 19, 11 per cent) (P = 0\u00b7014). Notably, rupture occurred in 17 of 46 tumours (37 per cent) with deletions involving codons 557 and 558 (del557\/558) versus 15 of 109 (13\u00b78 per cent) with other exon 11 mutations (P = 0\u00b7002). This association was confined to gastric tumours: 12 of 34 (35 per cent) with del557\/558 ruptured versus six of 77 (8 per cent) with other exon 11 mutations (P = 0\u00b7001). In multivariable logistic regression analysis, del557\/558 and tumour size were associated with an increased likelihood of tumour rupture, but mitotic count was not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Gastric GISTs with KIT exon 11 deletions involving codons 557 and 558 are at increased risk of tumour rupture. This high-risk feature can be identified in the diagnostic evaluation and should be included in the assessment when neoadjuvant imatinib treatment is considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.10743","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T11:43:20Z","timestamp":1516189400000},"page":"e169-e175","source":"Crossref","is-referenced-by-count":25,"title":["Genotype and risk of tumour rupture in gastrointestinal stromal tumour"],"prefix":"10.1093","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5552-6283","authenticated-orcid":false,"given":"K","family":"Boye","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Department of Tumour Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M","family":"Berner","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Hompland","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8 S","family":"Bruland","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Stoldt","sequence":"additional","affiliation":[{"name":"Department of Abdominal and Paediatric Surgery, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sundby Hall","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bjerkehagen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Department of Oral Biology, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2461-9089","authenticated-orcid":false,"given":"T","family":"H\u00f8lmebakk","sequence":"additional","affiliation":[{"name":"Department of Abdominal and Paediatric Surgery, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"2021020617165155400_bjs10743-bib-0001","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/bjs.7222","article-title":"Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour","volume":"97","author":"Hohenberger","year":"2010","journal-title":"Br J Surg"},{"key":"2021020617165155400_bjs10743-bib-0002","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/bjs.10104","article-title":"Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine","volume":"103","author":"H\u00f8lmebakk","year":"2016","journal-title":"Br J Surg"},{"key":"2021020617165155400_bjs10743-bib-0003","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/cncr.28669","article-title":"Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib","volume":"120","author":"Joensuu","year":"2014","journal-title":"Cancer"},{"key":"2021020617165155400_bjs10743-bib-0004","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s10120-014-0386-7","article-title":"Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy","volume":"18","author":"Yanagimoto","year":"2015","journal-title":"Gastric Cancer"},{"key":"2021020617165155400_bjs10743-bib-0005","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","article-title":"Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas","volume":"33","author":"Casali","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021020617165155400_bjs10743-bib-0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/SLA.0b013e3182a15eb7","article-title":"American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial","volume":"258","author":"DeMatteo","year":"2013","journal-title":"Ann Surg"},{"key":"2021020617165155400_bjs10743-bib-0007","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"2021020617165155400_bjs10743-bib-0008","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2021020617165155400_bjs10743-bib-0009","doi-asserted-by":"crossref","first-page":"iii21","DOI":"10.1093\/annonc\/mdu255","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"The ESMO\/European Sarcoma Network Working Group","year":"2014","journal-title":"Ann Oncol"},{"key":"2021020617165155400_bjs10743-bib-0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"2021020617165155400_bjs10743-bib-0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"key":"2021020617165155400_bjs10743-bib-0012","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1158\/1078-0432.CCR-14-1677","article-title":"Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST","volume":"20","author":"Wozniak","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021020617165155400_bjs10743-bib-0013","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1200\/JCO.2005.19.554","article-title":"Deletions affecting codons 557\u2013558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)","volume":"23","author":"Mart\u00edn","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021020617165155400_bjs10743-bib-0014","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.11323","article-title":"Spanish Group for Sarcoma Research. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors","volume":"106","author":"Wardelmann","year":"2003","journal-title":"Int J Cancer"},{"key":"2021020617165155400_bjs10743-bib-0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/annonc\/mdr127","article-title":"Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience","volume":"23","author":"Wozniak","year":"2012","journal-title":"Ann Oncol"},{"key":"2021020617165155400_bjs10743-bib-0016","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"Fletcher","year":"2013","edition":"4th"},{"key":"2021020617165155400_bjs10743-bib-0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021020617165155400_bjs10743-bib-0018","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3109\/0284186X.2013.770920","article-title":"Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H","volume":"52","author":"Revheim","year":"2013","journal-title":"Acta Oncol"},{"key":"2021020617165155400_bjs10743-bib-0019","first-page":"4331","article-title":"Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice","volume":"29","author":"Revheim","year":"2009","journal-title":"Anticancer Res"},{"key":"2021020617165155400_bjs10743-bib-0020","volume-title":"National Comprehensive Cancer Network Guidelines. Version 2.2017. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma","author":"National Comprehensive Cancer Network"},{"key":"2021020617165155400_bjs10743-bib-0021","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1245\/s10434-014-3632-7","article-title":"Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors","volume":"21","author":"Bednarski","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2021020617165155400_bjs10743-bib-0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J Surg Oncol"},{"key":"2021020617165155400_bjs10743-bib-0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejso.2012.09.004","article-title":"Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib","volume":"39","author":"Tielen","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"2021020617165155400_bjs10743-bib-0024","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1245\/s10434-011-2190-5","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132","volume":"19","author":"Wang","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2021020617165155400_bjs10743-bib-0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bjc.6605117","article-title":"Prognosis and predictive value of KIT exon 11 deletion in GISTs","volume":"101","author":"Bachet","year":"2009","journal-title":"Br J Cancer"},{"key":"2021020617165155400_bjs10743-bib-0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2015.10.069","article-title":"Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group","volume":"52","author":"Patrikidou","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021020617165155400_bjs10743-bib-0027","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-15-2748","article-title":"KIT exon 11 codons 557\u2013558 deletion mutation promotes liver metastasis through the CXCL12\/CXCR4 axis in gastrointestinal stromal tumors","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.10743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/105\/2\/e169\/36206484\/bjs10743.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/105\/2\/e169\/36206484\/bjs10743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T14:19:09Z","timestamp":1621520349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/105\/2\/e169-e175\/6122957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,17]]},"published-print":{"date-parts":[[2018,1,17]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.10743","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1]]}}}